SRPT ▼ -0.1% - Sarepta Therapeutics, Inc.
$SRPT - Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
14-OCT-2026 08:40 AM ET
Share this post
More filings for $SRPT
SRPT ▼ -2.3% - Sarepta Therapeutics, Inc.Sep 30, 2026SRPT ▲ +1.2% - Sarepta Therapeutics, Inc.Sep 30, 2026SRPT ▲ +0.9% - Sarepta Therapeutics, Inc.Sep 25, 2026SRPT ▼ -0.8% - Sarepta Therapeutics, Inc.Sep 24, 2026SRPT ▼ -0.8% - Sarepta Therapeutics, Inc.Sep 24, 2026SRPT ▼ -13.6% - Sarepta Therapeutics, Inc.Sep 8, 2026
View full $SRPT filing history →💬 Comments
Loading comments…
Leave a comment